Discovery and Model-Informed Drug Development of a Controlled-Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain.
Hopkins SC, Toongsuwan S, Corriveau TJ, Watanabe T, Tsushima Y, Asada T, Lew R, Shi L, Zann V, Snowden TJ, van der Graaf PH, Darpo B, Searle GE, Rabiner EA, Wilding I, Szabo ST, Galluppi GR, Koblan KS.
Hopkins SC, et al. Among authors: darpo b.
Clin Pharmacol Ther. 2024 Aug;116(2):460-470. doi: 10.1002/cpt.3311. Epub 2024 May 31.
Clin Pharmacol Ther. 2024.
PMID: 38822554